Rehabilitation through exercise prescription for cardiac patients using an artificial intelligence-based programme - RECAP

Rehabilitation through Exercise prescription for Cardiac patients using an Artificial Intelligence-based Programme - RECAP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN97352737

Enrollment

Registered

2022-11-17

Start date

2022-11-21

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Service users requiring cardiac rehabilitation Other

Interventions

This study will be done in two phases. The first phase, a single-arm study of 20 patients, will aim to determine if an in-house home rehabilitation app we have developed could successfully be used alo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients eligible for cardiac rehabilitation

Exclusion criteria

Exclusion criteria: 1. Awaiting urgent surgery 2. Unstable angina 3. Pregnancy 4. Currently enrolled in another interventional clinical trial or experiment 5. Malignant arrhythmias 6. Contraindications to rehabilitation - e.g. 6.1. Severe musculoskeletal conditions affecting exercise ability 6.2. Acute systemic illness or fever 6.3. Acute pericarditis or myocarditis 6.4. Uncontrolled atrial or ventricular arrhythmias 6.5. Uncontrolled sinus tachycardia 6.6. Aortic stenosis associated with pre-syncope/syncope 6.7. Uncompensated Heart failure 6.8. Complete atrioventricular block without a pacemaker 6.9. Recent embolism

Design outcomes

Primary

Measure	Time frame
Feasibility of conducting a large-scale randomised controlled trial measured using participant recruitment and dropout rates, acceptability of the intervention and the feasibility of randomisation at 12 weeks	—

Secondary

Measure	Time frame
1. Aerobic capacity and endurance measured using the 6-minute walk test at baseline and 8 weeks 2. Health-related quality of life measured using EQ-5D-5L questionnaire at baseline and 8 weeks 3. Health-related quality of life measured using SF-36 questionnaire at baseline and 8 weeks 4. Anxiety and depression assessed using HADS questionnaire at baseline and 8 weeks 5. Impact on quality of life measured using PROM-CR questionnaire at 8 weeks 6. Performance in activities of daily living measured using Barthel Index questionnaire at baseline and 8 weeks 7. Adherence to the intervention, including usage of the app measured using app s at 8 weeks	—

Measure

Time frame

1. Aerobic capacity and endurance measured using the 6-minute walk test at baseline and 8 weeks 2. Health-related quality of life measured using EQ-5D-5L questionnaire at baseline and 8 weeks 3. Health-related quality of life measured using SF-36 questionnaire at baseline and 8 weeks 4. Anxiety and depression assessed using HADS questionnaire at baseline and 8 weeks 5. Impact on quality of life measured using PROM-CR questionnaire at 8 weeks 6. Performance in activities of daily living measured using Barthel Index questionnaire at baseline and 8 weeks 7. Adherence to the intervention, including usage of the app measured using app s at 8 weeks

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 14, 2026